News
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 5, 2023
ALK-001 (C20-D3-Vitamin A) slows the growth of atrophic lesions in ABCA4-related Stargardt Disease: Results of a Phase 2 placebo-controlled clinical trial (TEASE study)
June 1, 2022
C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model
December 1, 2021
Alkeus Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021
Vitamin A cycle byproducts impede dark adaptation
September 1, 2021
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
July 14, 2021
TEASE: a phase 2 clinical trial assessing the tolerability and effects of oral once-a-day ALK-001 on Stargardt disease
September 1, 2016
Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies?
January 1, 2016